Cargando…
COVID-19 severity scale for claims data research
OBJECTIVE: To create and validate a methodology to assign a severity level to an episode of COVID-19 for retrospective analysis in claims data. DATA SOURCE: Secondary data obtained by license agreement from Optum provided claims records nationally for 19,761,754 persons, of which, 692,094 persons ha...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131339/ https://www.ncbi.nlm.nih.gov/pubmed/37101164 http://dx.doi.org/10.1186/s12913-023-09362-2 |
_version_ | 1785031157288534016 |
---|---|
author | Krause, Trudy Millard Greenberg, Raymond Ghosh, Lopita Wozny, Joseph S. Hansen, Regina M. Schaefer, Caroline |
author_facet | Krause, Trudy Millard Greenberg, Raymond Ghosh, Lopita Wozny, Joseph S. Hansen, Regina M. Schaefer, Caroline |
author_sort | Krause, Trudy Millard |
collection | PubMed |
description | OBJECTIVE: To create and validate a methodology to assign a severity level to an episode of COVID-19 for retrospective analysis in claims data. DATA SOURCE: Secondary data obtained by license agreement from Optum provided claims records nationally for 19,761,754 persons, of which, 692,094 persons had COVID-19 in 2020. STUDY DESIGN: The World Health Organization (WHO) COVID-19 Progression Scale was used as a model to identify endpoints as measures of episode severity within claims data. Endpoints used included symptoms, respiratory status, progression to levels of treatment and mortality. DATA COLLECTION/EXTRACTION METHODS: The strategy for identification of cases relied upon the February 2020 guidance from the Centers for Disease Control and Prevention (CDC). PRINCIPAL FINDINGS: A total of 709,846 persons (3.6%) met the criteria for one of the nine severity levels based on diagnosis codes with 692,094 having confirmatory diagnoses. The rates for each level varied considerably by age groups, with the older age groups reaching higher severity levels at a higher rate. Mean and median costs increased as severity level increased. Statistical validation of the severity scales revealed that the rates for each level varied considerably by age group, with the older ages reaching higher severity levels (p < 0.001). Other demographic factors such as race and ethnicity, geographic region, and comorbidity count had statistically significant associations with severity level of COVID-19. CONCLUSION: A standardized severity scale for use with claims data will allow researchers to evaluate episodes so that analyses can be conducted on the processes of intervention, effectiveness, efficiencies, costs and outcomes related to COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-09362-2. |
format | Online Article Text |
id | pubmed-10131339 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101313392023-04-27 COVID-19 severity scale for claims data research Krause, Trudy Millard Greenberg, Raymond Ghosh, Lopita Wozny, Joseph S. Hansen, Regina M. Schaefer, Caroline BMC Health Serv Res Research OBJECTIVE: To create and validate a methodology to assign a severity level to an episode of COVID-19 for retrospective analysis in claims data. DATA SOURCE: Secondary data obtained by license agreement from Optum provided claims records nationally for 19,761,754 persons, of which, 692,094 persons had COVID-19 in 2020. STUDY DESIGN: The World Health Organization (WHO) COVID-19 Progression Scale was used as a model to identify endpoints as measures of episode severity within claims data. Endpoints used included symptoms, respiratory status, progression to levels of treatment and mortality. DATA COLLECTION/EXTRACTION METHODS: The strategy for identification of cases relied upon the February 2020 guidance from the Centers for Disease Control and Prevention (CDC). PRINCIPAL FINDINGS: A total of 709,846 persons (3.6%) met the criteria for one of the nine severity levels based on diagnosis codes with 692,094 having confirmatory diagnoses. The rates for each level varied considerably by age groups, with the older age groups reaching higher severity levels at a higher rate. Mean and median costs increased as severity level increased. Statistical validation of the severity scales revealed that the rates for each level varied considerably by age group, with the older ages reaching higher severity levels (p < 0.001). Other demographic factors such as race and ethnicity, geographic region, and comorbidity count had statistically significant associations with severity level of COVID-19. CONCLUSION: A standardized severity scale for use with claims data will allow researchers to evaluate episodes so that analyses can be conducted on the processes of intervention, effectiveness, efficiencies, costs and outcomes related to COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-09362-2. BioMed Central 2023-04-26 /pmc/articles/PMC10131339/ /pubmed/37101164 http://dx.doi.org/10.1186/s12913-023-09362-2 Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Krause, Trudy Millard Greenberg, Raymond Ghosh, Lopita Wozny, Joseph S. Hansen, Regina M. Schaefer, Caroline COVID-19 severity scale for claims data research |
title | COVID-19 severity scale for claims data research |
title_full | COVID-19 severity scale for claims data research |
title_fullStr | COVID-19 severity scale for claims data research |
title_full_unstemmed | COVID-19 severity scale for claims data research |
title_short | COVID-19 severity scale for claims data research |
title_sort | covid-19 severity scale for claims data research |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131339/ https://www.ncbi.nlm.nih.gov/pubmed/37101164 http://dx.doi.org/10.1186/s12913-023-09362-2 |
work_keys_str_mv | AT krausetrudymillard covid19severityscaleforclaimsdataresearch AT greenbergraymond covid19severityscaleforclaimsdataresearch AT ghoshlopita covid19severityscaleforclaimsdataresearch AT woznyjosephs covid19severityscaleforclaimsdataresearch AT hansenreginam covid19severityscaleforclaimsdataresearch AT schaefercaroline covid19severityscaleforclaimsdataresearch |